Replies to post #21132 on Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

it has already gone generic so commercialization could be upon approval/partnership

Yes Grill, and also that $2.4 BILLION is a market that won't eventually get cut in half once all the generics arrive... in fact it's $2.4 BILLION and GROWING!!!

It's a pretty crowded field... 17 suppliers on the 500mg and 15 on the 750mg... but when you figure that each 1% equals $24 million dollars it doesn't take that big a market share to make a material difference to IPCI.

Considering it probably gets 40% in royalties and cost PLUS profit on manufacturing... loosely figuring that should equate to approximately $10 million a year to IPCI's bottom line for every 1% of the market captured.

[Samsa]

Grill.....a great catch on that approval. you are correct it would be nice to get another ANDA approval. I agree with Angelo in another post. he stated while there are plenty of generics on the market this one is big enough to make an impact for IPCI. just a lousy 4 million a year in revenue would put us way over the top considering we have Focalin and Seroquel. I don't know how much longer the FDA can sit on our backlogged applications. bust if you go off their own goal of cleaning up by September of 2017 we should see an approval on an average of 1 every other month from now until then. ! that's not chump change.

[dtstx]

Nice grill, that actually came out this morning as they always post them a day late. I also looked last night and none of the 13th approvals were listed, as the norm. Regardless, these last (2) were both filed after the IPCI submission which bodes well for our future approval.

[Tekterra]

Unfortunately Metformin Glucophage XR is not partnered with Mallinckrodt. Likely there are more deals in the works. Hope you're right we get a nice surprise.

However, it kind of sucked others are getting approval but not IPCI. This one has a lot of generic competition though.